Affordable Access

deepdyve-link
Publisher Website

The OptiLUTS trial: improving care for therapy-resistant symptoms of the pelvis in Belgium.

Authors
  • Ghijselings, Lynn1
  • Van De Putte, Dirk2
  • Hervé, François1, 3
  • Goessaert, An-Sofie1
  • Beeckman, Dimitri4
  • Pattyn, Piet3
  • Everaert, Karel1
  • 1 Urology Department, Ghent University Hospital, Ghent University , Ghent, Belgium. , (Belgium)
  • 2 Colorectal Surgery, Ghent University Hospital, Ghent University , Ghent, Belgium. , (Belgium)
  • 3 Urology Department, UCL University Hospital , Woluwe, Belgium. , (Belgium)
  • 4 Department of Public Health and Primary Care, Ghent University Hospital, Ghent University , Ghent, Belgium. , (Belgium)
Type
Published Article
Journal
Acta clinica Belgica
Publication Date
Oct 01, 2020
Volume
75
Issue
5
Pages
334–339
Identifiers
DOI: 10.1080/17843286.2019.1630109
PMID: 31210620
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The management of therapy-resistant lower urinary tract symptoms (LUTS) and symptoms resulting from pelvic organ dysfunctions are subject to a high variability in the Belgian health-care centres. Practical guidelines and standardized patient clinical care pathways are often lacking and unadapted to the Belgian healthcare system. The OptiLUTS trial aims to improve the multidisciplinary care of therapy-resistant symptoms of the pelvis in the Belgian healthcare setting. Project A aims for the improvement of knowledge of 2nd line treatments for LUTS among general practitioners. In project B a treatment algorithm for the overactive bladder syndrome and non-obstructive urinary retention will be developed specifically for Belgium. In Project C a patient customized sacral neuromodulation (SNM) care pathway will be set up. Part A: Explorative study among general practitioners by distribution of a questionnaire. Part B: Review of existing guidelines and use of the Delphi method to obtain expert consensus. Part C: A single center comparative study to compare outcomes before and after implementation of the SNM care pathway. Patients scheduled for the first stage of Interstim therapy™ will be included (N=100). Primary endpoints are the sensitivity and specificity of a new pelvic symptom assessment tool, the conversion to implant and explantation rates. There is a margin for improvement in the care process of patients with therapy-resistant symptoms of the pelvis in the Belgium healthcare system. In the OptiLUTs trial adapted guidelines and a clinical care pathway will be developed to standardize and increase the efficiency of care. Approval for the trial by the Ethics Committee of the Ghent University hospital: EC/2018/0244.

Report this publication

Statistics

Seen <100 times